scholarly journals Effect of xenon on pain severity and adaptational status of neuro-oncological and oncogynecological patients

2019 ◽  
Vol 19 (1S) ◽  
pp. 228-230 ◽  
Author(s):  
N N Popova ◽  
M S Zinkovich ◽  
A I Shikhlyarova ◽  
G V Zhukova ◽  
L Ya Rozenko ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Visual Analogue Scale ◽  
Brain Metastases ◽  
Radical Hysterectomy ◽  
Analgesic Effect ◽  
Analogue Scale ◽  
Whole Brain Radiotherapy ◽  
The Body ◽  
Brain Radiotherapy ◽  
Hematological Indicators

The severity of pain and changes in the adaptational status were studied in patients with brain metastases or cervical cancer receiving xenon therapy after whole brain radiotherapy or after radical hysterectomy. Hematological indicators of the nature and tensiton of general nonspecific adaptional reactions of the body (ARs) by Garkavi-Kvakina-Ukolova, the QLQ-C15 questionnaire and a 10-point graphic visual analogue scale for the assessment of the intensity of pain were used. Xenon caused concurrent reduce in the intensity of pain and improvement of characteristics of ARs in all studied patients. The results suggested an association between the analgesic effect of xenon and the normalization of neuroimmune processes and reduced damaging effects of special antitumor treatment on the body under the influence of xenon.

scholarly journals High neutrophil, low lymphocyte and hemoglobin unfavorably impact survival in non-small cell lung cancer patients with brain metastases

2020 ◽  
Author(s):  
Wang Li ◽  
Yanli Qu ◽  
Fengyun Wen ◽  
Xiaoyi He ◽  
Hongying Jia ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Cox Regression ◽  
Characteristic Curve ◽  
Whole Brain Radiotherapy ◽  
Clinical Problem ◽  
Cox Regression Analysis ◽  
Brain Radiotherapy ◽  
History Of ◽  
Hematological Indicators ◽  
Nsclc Patients

Abstract Background Brain metastases (BM) from NSCLC has emerged as an increasingly corresponding clinical problem. Precise prognostic evaluation is the basis for personalized medicine. This study sought to investigate prognostic values of clinical and hematological indicators for NSCLC patients with BM in the real world, which could further help guide survivorship care in the actual clinical setting and clinical trials. Materials and Methods We retrospectively reviewed the clinical and hematological indicators of NSCLC patients with BM treated with whole-brain radiotherapy. Receiver operating characteristic curve was performed to evaluate the optimal cut-off point. Kaplan–Meier survival analysis and Cox regression analyses were used to evaluate survival. Results 105 patients were included and median survival was 21 months (range: 1–64 months). Univariate analyses demonstrated that favorable survival was associated with resection history of NSCLC (P = 0.015), absent of intracranial symptom (P = 0.044), lymphocyte ≥ 1.54*109/L(P < 0.001), neutrophil < 4.64*109/L (P = 0.016), hemoglobin ≥ 117.5 g/L (P < 0.001), BSBM scores of 2–3 (P = 0.033) and Lung-molGPA scores of 2.5-4 (P < 0.001). Cox regression analysis showed that lymphocyte (HR 3.390, 95% CI 1.869–6.151, P < 0.001), neutrophil (HR 0.517, 95% CI 0.286–0.934, P = 0.029), hemoglobin (HR 3.215, 95% CI 1.748–5.911, P < 0.001), resection history of NSCLC(HR 2.813, 95% CI 1.375–5.754, P = 0.005), intracranial symptom(HR 0.251, 95% CI 0.113–0.561, P = 0.001), and Lung-molGPA(HR 2.317, 95% CI 1.186–4.527, P = 0.014) were independent prognostic factors for NSCLC patients with BM. Conclusions High neutrophil, low lymphocyte and hemoglobin, absent of resection history of NSCLC, present of intracranial symptom, and Lung-molGPA scores of 0–2 may provide valuable information for indicating poor prognosis in NSCLC patients with BM .

scholarly journals Dural and Multiple Brain Metastases From Basaloid Nasopharyngeal Carcinoma: Case Report and Literature Review

2021 ◽  
Vol 11 ◽  
Author(s):  
Xiaotao Geng ◽  
Furong Hao ◽  
Guiyan Han ◽  
Yaping Zhang ◽  
Peiyan Qin
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Brain Metastases ◽  
Southern China ◽  
Nasal Congestion ◽  
Whole Brain Radiotherapy ◽  
The Body ◽  
Multiple Brain Metastases ◽  
Brain Radiotherapy ◽  
Multiple Metastases ◽  
The Right

BackgroundNasopharyngeal carcinoma is an endemic head and neck cancer in Southern China. The common metastases organs involve bone, lung, and liver. Metastases in the dura and at multiple locations in the brain after a diagnosis of nasopharyngeal carcinoma are extremely rare.Case PresentationWe present a case of a 66-year-old man who initially complained of nasal congestion, epistaxis, and hearing impairment. The biopsy of the nasopharynx lesion showed basaloid squamous cell carcinoma. Eight months after conventional therapy, the patient was admitted to our hospital again with the complaint of a headache. A PET/CT scan was performed, revealing multiple metastases. A biopsy of subcutaneous soft tissue from the right upper arm was consistent with the previous biopsy. Palliative chemotherapy was administered. Thereafter, the patient had sudden dysfunction of the right side of the body. MRI demonstrated dural and multiple brain metastases. The therapeutic regimen then consisted of whole-brain radiotherapy, anti-angiogenesis therapy, and immunotherapy.ConclusionsThis case highlights the diagnosis and treatment of uncommon metastases of nasopharyngeal carcinoma. Clinicians should remain vigilant for metastases during the treatment and follow-up periods.

scholarly journals Brain Metastases from Endometrial Carcinoma

ISRN Oncology ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-13 ◽  
Author(s):  
Ettie Piura ◽  
Benjamin Piura
Keyword(s):  
Brain Metastasis ◽  
Brain Metastases ◽  
Endometrial Carcinoma ◽  
Primary Source ◽  
Whole Brain Radiotherapy ◽  
Endometrial Biopsy ◽  
The Body ◽  
Unknown Primary ◽  
Brain Radiotherapy ◽  
Disseminated Disease

This paper will focus on knowledge related to brain metastases from endometrial carcinoma. To date, 115 cases were documented in the literature with an incidence of 0.6% among endometrial carcinoma patients. The endometrial carcinoma was usually an advanced-stage and high-grade tumor. In most patients (~90%), brain metastasis was detected after diagnosis of endometrial carcinoma with a median interval from diagnosis of endometrial carcinoma to diagnosis of brain metastases of 17 months. Brain metastasis from endometrial carcinoma was either an isolated disease limited to the brain only (~50%) or part of a disseminated disease involving also other parts of the body (~50%). Most often, brain metastasis from endometrial carcinoma affected the cerebrum (~75%) and was solitary (~60%). The median survival after diagnosis of brain metastases from endometrial carcinoma was 5 months; however, a significantly better survival was achieved with multimodal therapy including surgical resection or stereotactic radiosurgery followed by whole brain radiotherapy (WBRT) and/or chemotherapy compared to WBRT alone. It is suggested that brain imaging studies should be considered in the routine follow up of patients with endometrial carcinoma and that the search for a primary source in females with brain metastases of unknown primary should include endometrial biopsy.

Prognostic factors and survival after whole-brain radiotherapy for initial brain metastases arising from non-small cell lung cancer

2021 ◽  
pp. 1-6
Author(s):  
Yukinori Okada ◽  
Mariko Kobayashi ◽  
Mio Shinozaki ◽  
Tatsuyuki Abe ◽  
Naoki Nakamura
Keyword(s):  
Prognostic Factors ◽  
Brain Metastasis ◽  
Brain Metastases ◽  
Gene Mutation ◽  
Stage Iv ◽  
Whole Brain Radiotherapy ◽  
Hazard Ratio ◽  
Small Cell Lung ◽  
Mutation Status ◽  
Brain Radiotherapy

Abstract Aim: To identify prognostic factors and investigate patient survival after whole-brain radiotherapy (WBRT) for initial brain metastases arising from non-small cell lung cancer (NSCLC). Methods: Patients diagnosed with NSCLC between 1 January 2010 and 30 September 2019, and who received WBRT upon first developing a brain metastasis, were investigated. Overall survival was determined as related to age, sex, duration between initial examination and brain metastasis detection, stage at the first examination, presence of metastases outside the brain, blood analysis findings, brain metastasis symptoms, radiotherapy dose and completion, imaging findings, therapeutic course of chemotherapy and/or radiation therapy, histological type, and gene mutation status. Results: Thirty-one consecutive patients (20 men and 11 women) with a mean age of 63·8 years and median survival of 129 days were included. Multivariate analysis with stepwise testing was performed to investigate differences in survival according to gene mutation status, lactate dehydrogenase (LDH) level, irradiation dose, WBRT completion and Stage status. Of these, a statistically significant difference in survival was observed in patients with gene mutation status (hazard ratio: 0·31, 95% CI: 0·11–0·86, p = 0·025), LDH levels <230 vs. ≥230 IU/L (hazard ratio: 4·08, 95% CI: 1·45–11·5, p < 0·01) received 30 Gy, 30 Gy/10 fractions to 35 Gy/14 fractions, and 37·5 Gy/15 fractions (hazard ratio: 0·26, 95% CI: 0·09–0·71, p < 0·01), and stage IV versus non-stage IV (hazard ratio: 0·13, 95 CI:0·02–0·64, p < 0·01) Findings: Gene mutation, LDH, radiation dose and Stage are prognostic factors for patients with initial brain metastases who are treated with WBRT.

scholarly journals A Dutch phase III randomized multicenter trial: whole brain radiotherapy vs. stereotactic radiotherapy for 4-10 brain metastases

2021 ◽  
Author(s):  
Dianne Hartgerink ◽  
Anna Bruynzeel ◽  
Danielle Eekers ◽  
Ans Swinnen ◽  
Coen Hurkmans ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Brain Metastases ◽  
Survival Rates ◽  
Whole Brain Radiotherapy ◽  
Phase Iii ◽  
Whole Brain ◽  
Brain Radiotherapy ◽  
One Year

Abstract Background The clinical value of whole brain radiotherapy (WBRT) for brain metastases (BM) is a matter of debate due to the significant side effects involved. Stereotactic radiosurgery (SRS) is an attractive alternative treatment option that may avoid these side effects and improve local tumor control. We initiated a randomized trial (NCT02353000) to investigate whether quality of life is better preserved after SRS compared with WBRT in patients with multiple brain metastases. Methods Patients with 4 to 10 BM were randomized between the standard arm WBRT (total dose 20 Gy in 5 fractions) or SRS (single fraction or 3 fractions). The primary endpoint was the difference in quality of life (QOL) at three months post-treatment. Results The study was prematurely closed due to poor accrual. A total of 29 patients (13%) were randomized, of which 15 patients have been treated with SRS and 14 patients with WBRT. The median number of lesions were 6 (range, 4-9) and the median total treatment volume was 13.0 cc 3 (range, 1.8-25.9 cc 3). QOL at three months decreased in the SRS group by 0.1 (SD=0.2), compared to 0.2 (SD=0.2) in the WBRT group (p=0.23). The actuarial one-year survival rates were 57% (SRS) and 31% (WBRT) (p=0.52). The actuarial one-year brain salvage-free survival rates were 50% (SRS) and 78% (WBRT) (p=0.22). Conclusion In patients with 4 to 10 BM, SRS alone resulted in one-year survival for 57% of patients while maintaining quality of life. Due to the premature closure of the trial, no statistically significant differences could be determined.

scholarly journals Whole-brain radiotherapy in patients with brain metastases from melanoma

CNS Oncology ◽  
2014 ◽  
Vol 3 (6) ◽  
pp. 401-406 ◽  
Author(s):  
Macarena de la Fuente ◽  
Kathryn Beal ◽  
Richard Carvajal ◽  
Thomas J Kaley
Keyword(s):  
Brain Metastases ◽  
Whole Brain Radiotherapy ◽  
Whole Brain ◽  
Brain Radiotherapy

scholarly journals Current treatment of patients with multiple brain metastases

2000 ◽  
Vol 9 (2) ◽  
pp. 1-5 ◽  
Author(s):  
Steven D. Chang ◽  
John R. Adler
Keyword(s):  
Brain Metastases ◽  
Treatment Options ◽  
Whole Brain Radiotherapy ◽  
Mass Effect ◽  
Current Treatment ◽  
Rapid Reduction ◽  
Multiple Brain Metastases ◽  
Brain Radiotherapy ◽  
Multiple Metastases ◽  
Difficult Challenge

The management of patients with multiple brain metastases remains a difficult challenge for neurosurgeons. This patient population has a poor prognosis when compared with those harboring a solitary brain metastasis, and historically treatment has generally consisted of administering whole-brain radiotherapy once the diagnosis of multiple brain metastases is made. Resection can be useful in a subset of patients with multiple metastases in whom one or two of the lesions are symptomatic, as this may provide rapid reduction of mass effect and edema. Furthermore, the authors of recent studies have shown that stereotactic radiosurgery can be used in certain patients with multiple brain metastases as part of the treatment regimen. In this review the authors outline the treatment options and indications as well as a management strategy for the treatment of patients with multiple brain metastases.

Sign in / Sign up

Export Citation Format

Share Document